Immunotherapy, avelumab and protecting the immunocompromised

<p>This is the latest episode of the free DDW narrated podcast, “Immunotherapy, avelumab and protecting the immunocompromised", which covers three articles written for Volume 23, Issue 3 – Summer 2022 of DDW. They are called “<a href= "https://www.ddw-online.com/how-mice-with-humanised-immune-systems-are-advancing-cell-based-immunotherapy-17953-202207/">Mice with humanised immune systems advance cell-based immunotherapy”</a>, “<a href= "https://www.ddw-online.com/the-avelumab-story-and-what-it-means-for-urothelial-carcinoma-17690-202207/">The avelumab story and what it means for urothelial carcinoma</a>”, and “<a href= "https://www.ddw-online.com/why-immunocompromised-people-are-still-forgotten-when-it-comes-to-viral-protection-17706-202207/">Immunocompromised are ‘forgotten’ when it comes to viral protection</a>”.</p> <p class="MsoNormal"><span style= "mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">In the first article, you will hear from Courtney Ferrebee, PhD, Field Applications Scientist, Taconic Biosciences.</span></p> <p class="MsoNormal"><span style= "mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">In the second article, Lu Rahman speaks to Dr Stuart Hill, Medical Director for Merck, about the development of the avelumab and what this means for the treatment of bladder cancer.</span></p> <p class="MsoNormal"><span style= "mso-bidi-font-family: Calibri; mso-bidi-theme-font: minor-latin;">In the third article, Dr. Jeffery Stein, CEO of Cidara and an expert in viral diseases, talks about the drug-Fc conjugate (DFCs), a new class of immunotherapeutic antivirals.</span></p>